High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures

“I propose that we are entering a new era for drug-discovery bioanalysis. I believe that we are already starting to have a true paradigm shift on how we perform our quantitative assays in support of lead optimization efforts.” The use of HPLC combined with MS/MS has been the state-of-the-art analytical tool for drug-discovery bioanalysis (BA) for almost two decades [1–3]. Over that time, the HPLC systems have improved and evolved, with perhaps the biggest change in recent years when UPLC became commercially available [4–6]. While MS/MS systems have also improved over those two decades, the basic principle of using selected...

To view this content, please register now for access

It's completely free